The pituitary uptake of 111In-DTPA-D-Phe1-octreotide in the normal pituitary and in pituitary adenomas

Journal of Endocrinological Investigation

Volumn 22, Issue 3, 1999, Pages 176-183

  Colao, Annamaria ^b   Lastoria, S ^c   Ferone, D ^c   Varrella, P ^c   Marzullo, P ^c   Pivonello, R ^c   Cerbone, G ^c   Acampa, W ^c   Salvatore, M ^a   Lombardi, G ^c  

^a CNR   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c NONE

Author keywords

CH; Neuroendocrine tumors; Octreotide; Pituitary adenomas; Somatostatin; Somatostatin receptors

Indexed keywords

GROWTH HORMONE; OCTREOTIDE; PENTETATE INDIUM IN 111; PROLACTIN; SOMATOMEDIN C; DIAGNOSTIC AGENT; DRUG DERIVATIVE; INDIUM; PENTETIC ACID; RADIOPHARMACEUTICAL AGENT; SDZ 215 811; SDZ 215-811;

ACROMEGALY; ADOLESCENT; ADULT; AGED; ARTICLE; CANCER REGRESSION; CARCINOID; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG UPTAKE; FEMALE; GROWTH HORMONE RELEASE; HUMAN; HYPOPHYSIS ADENOMA; INSULINOMA; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; MELANOMA; NEUROENDOCRINE TUMOR; NUCLEAR MAGNETIC RESONANCE IMAGING; SCINTIGRAPHY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SUBCUTANEOUS DRUG ADMINISTRATION; THYMOMA; THYROID CARCINOMA; ADENOMA; HYPOPHYSIS; HYPOPHYSIS TUMOR; METABOLISM; MIDDLE AGED; SCINTISCANNING;

ADENOMA; ADOLESCENT; ADULT; AGED; FEMALE; HUMANS; INDIUM RADIOISOTOPES; MALE; MIDDLE AGED; OCTREOTIDE; PENTETIC ACID; PITUITARY GLAND; PITUITARY NEOPLASMS; RADIOPHARMACEUTICALS;

EID: 0032586754     PISSN: 03914097     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03343538     Document Type: Article

References (21)

1. Lamberts S.W.J., van Der Lely A-J., De Herder W.W., Hofland L.J. Octreotide. N. Engl. J. Med. 334: 246, 1996.
2. Reubi J.C., Landolt A.M. High density of somatostatin receptors in pituitary tumors from acromegalic patients. J. Clin. Endocrinol. Metab. 59: 1148, 1984.
3. Ikuyama S., Nawata H., Kato K., Karshima T., Ibayashi H., Nagakaki H. Specific somatostatin receptors on human pituitary adenoma cell membrane. J. Clin. Endocrinol. Metab. 61: 666, 1985.
4. Reubi J.C., Heitz P.U., Landolt A.M. Visualization of somatostatin receptors and correlation with immunoreactive growth hormone and prolactin in human pituitary adenomas evidence for different tumor subclasses. J. Clin. Endocrinol. Metab. 65: 65, 1987.
5. Reubi J.C. Use of receptors autoradiography to measure the somatostatin receptor status in pituitary adenomas and other neuroendocrine tumors. In: Casanueva F.F., Dieguez C. (Eds.), Recent advances in basic and clinical neuroendocrinology. Int. Congr. Ser. 864. Amsterdam, Excepta Medica, 1989, p. 285.
6. Lamberts S.W.J., Uitterlinden P., Schuijff P.C., Klijn G.C. Therapy of acromegaly with sandostatin: the predictive value of an acute test, the value of serum somatomedin-C measurements in dose adjustement and the definition of a biochemical "cure". Clin. Endocrinol. 29: 411, 1988.
7. Colao A., Ferone D., Lastoria S., Marzullo P., Cerbone G., Di Sarno A., Longobardi S., Merola B., Salvatore M., Lombardi G. Prediction of efficacy of octreotide therapy in patients with acromegaly. J. Clin. Endocrinol. Metab. 81: 2356, 1996.
8. Lamberts S.W.J., Krenning E.P., Reubi J.C. The role of somatostatin and its analogs in the diagnosis and treatment of tumors. Endocr. Rev. 12: 450, 1990.
9. Faglia G., Bazzoni N., Spada A., Arosio M., Ambrosi B., Spinelli F., Sara R., Bonino C., Lunghi F. In vivo detection of somatostatin receptors in patients with functionless pituitary adenomas by means of radioiodinated analog of somatostatin ([123-I]SDZ 204-090). J. Clin. Endocrinol. Metab. 73: 850, 1991.
10. Ur E., Mather S.J., Bomanji J., Ellison D., Britton K.E., Grossman A.B., Wass J.A.H., Besser G.M. Pituitary imaging using a labelled somatostatin analogue in acromegaly. Clin. Endocrinol. 36: 147, 1992.
11. Broson-Chazot F., Houzard C., Ajzenberg C., Noucaudie M., Duet M., Mundler O., Marchandise X., Epelbaum J., Gomez De Alzaga M., Scäfer J., Meyerhof W., Sassolas G., Warnet A. Somatostatin receptor imaging in somatroph and non-functioning pituitary adenomas: correlation with hormonal and visual responses to octreotide. Clin. Endocrinol. 47: 589, 1997.
12. Plöckinger U., Reichel M., Fett U., Saeger W., Quabbe H-J. Preoperative octreotide treatment of growth hormone-secreting and clinically non-functioning pituitary macroadenomas: Effects on tumor volume and lack of correlation with immunohistochemistry and somatostatin receptor scintigraphy. J. Clin. Endocrinol. Metab. 79: 1416, 1994.
13. Plöckinger U., Bäder M., Hopfenmüller H., Saeger W., Quabbe H-J. Results of somatostatin receptor scintigraphy do not predict pituitary tumor volume and hormone-response to octreotide therapy and do not correlate with tumor histology. Eur. J. Endocrinol. 136: 369, 1997.
14. van Royen E.A., Verhoeff N.P.L.G., Meylaerts S.A.G., Miedema A.R. Indium-111-DTPA-octreotide uptake measured in normal and abnormal pituitary glands. J. Nucl. Med. 37: 1449, 1996.
15. Colao A., Di Sarno A., Landi M.L., Cirillo S., Samacchiaro F., Facciolli G., Pivonello R., Cataldi M., Merola B., Annunziato L., Lombardi G. Long-term and low dose treatment with cabergoline induces macroprolactinoma shrinkage. J. Clin. Endocrinol. Metab. 82: 3574, 1997.
16. Bakker W.H., Albert R., Bruns C., Breeman W.A.P., Hofland L.J., Marbach P., Pless J., Pralet V., Stolz B., Koper J.W., Lamberts S.W.J., Visser T.J., Krenning E.P. [111In-DTPA-D-Phe1]-octreotide, a potential radiopharmaceutical for imaging of somatostatin receptor-positive tumors: synthesis, radiolabeling and in vitro validation. Life Sci. 49: 1583, 1991.
17. De Bruin T.W.A., Kwekkeboom D.J., V'ant Verlaat J.W., Reubi J-C., Krenning E.P., Lamberts S.W.J., Croughs R.J.M. Clinically nonfunctioning pituitary adenoma and octreotide response to long term high dose treatment and studies in vitro. J. Clin. Endocrinol. Metab. 75: 1310, 1992.
18. Reubi J-C., Landolt A.M. High density o somatostatin receptors in pituitary tumors from acromegalic patients. Clin. Endocrinol. Metab. 59: 1148, 1984.
19. Merola B., Colao A., Ferone D., Selleri A., Di Sarno A., Marzullo P., Biondi B., Spaziante R., Rossi E., Lombardi G. Effects of a chronic treatment with octreotide in patients with functionless pituitary adenomas. Horm. Res. 40: 149, 1993.
20. Warnet A., Timsit J., Chanson P. The effect of somatostatin analogue an chiasmal dysfunction from pituitary macroadenomas. J. Neurosurg. 71: 687, 1989.
21. Chanson P. Predicting the effects of long-term medical treatment in acromegaly. At what cost? For what benefits? Eur. J. Endocrinol. 136: 359, 1997.